Topical Ointment for Discoid Lupus Ulcers
For discoid lupus erythematosus ulcers, use fluocinonide 0.05% cream (a potent topical corticosteroid) as first-line therapy, or clobetasol propionate 0.05% cream/ointment for more resistant lesions.
Primary Treatment Approach
The strongest evidence supports potent topical corticosteroids as the cornerstone of therapy for discoid lupus lesions:
Fluocinonide 0.05% cream demonstrated marked superiority over mild corticosteroids (hydrocortisone 1%), achieving clearing or excellent improvement in 27% of patients versus 10% with hydrocortisone—a clinically significant 17% absolute benefit (NNT=6) 1.
Clobetasol propionate 0.05% is an effective alternative for resistant lesions, with documented success in oral discoid lupus manifestations when applied via plastic carriers 2.
Application Strategy
Apply the potent topical corticosteroid directly to lesional skin:
- For localized disease: 10-20g daily on affected areas
- Continue treatment until lesions resolve, typically requiring several weeks
- Monitor for response within 1-3 weeks; if inadequate, consider increasing application frequency or switching agents
Alternative for Refractory Cases
Tacrolimus ointment 0.1% serves as a second-line option when corticosteroids fail or are contraindicated 3:
- Demonstrated clear improvement in 6 of 11 patients with resistant cutaneous lupus lesions
- Particularly useful for chronic therapy to avoid corticosteroid-related skin atrophy
- Apply for minimum 6 weeks before assessing response
- Caution: May cause burning sensation and peeling in some patients (led to discontinuation in 1 of 12 patients)
Clinical Pitfalls to Avoid
- Don't use mild corticosteroids (like hydrocortisone 1%)—they are significantly less effective than potent preparations 1
- Don't confuse with other ulcer types—the evidence for diabetic foot ulcers 4 or peptic ulcers 5 is irrelevant here
- Monitor for systemic lupus features—discoid lupus can coexist with or progress to systemic disease, particularly in patients with other autoimmune conditions 6
The evidence clearly favors potent topical corticosteroids as first-line therapy, with tacrolimus reserved for corticosteroid-resistant or corticosteroid-intolerant cases.